Department of Orthopedic Surgery, University of Toyama, Toyama, Japan.
Department of Orthopedic Surgery, University of Toyama, Toyama, Japan.
Biochem Biophys Res Commun. 2018 Mar 4;497(2):756-761. doi: 10.1016/j.bbrc.2018.02.147. Epub 2018 Feb 21.
The objective of the present study is to demonstrate that a newly developed selective c-Fos/activator protein (AP)-1 inhibitor, T-5224, inhibits the expression of matrix metalloproteinases (MMPs) in human articular chondrocytes, and prevents cartilage destruction in an osteoarthritis (OA)-induced mouse model. First, we examined the effect of T-5224 on MMP and inflammatory cytokine expression by real-time polymerase chain reaction in human articular chondrocytes. We created an OA model by destabilization of the medial meniscus (DMM) in mice. T-5224 was orally administered once a day and the OA pathology was assessed by histological, immunohistochemical, and micro-computed tomography (CT) analyses. T-5224 inhibited the mRNA expression levels of MMP-1, 3, and 13, and interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6 in IL-1-stimulated human chondrocytes. Oral administration of T-5224 to OA-induced mice prevented cartilage destruction. The histological scores for OA were significantly better in the T-5224-treated group than the vehicle-treated group. Type X collagen and MMP-13 were not increased in the T-5224-treated group by immunohistochemical staining. Micro-CT analysis showed mild but apparent osteophyte development in the femoral condyle and antero-medial aspect of the tibia in the vehicle-treated group but not in the T-5224-treated group. Taken together, specific inhibition of c-Fos/AP-1 and the resulting inhibition of the transactivation of a broad spectrum of downstream MMPs, along with inflammatory cytokines, effectively prevented cartilage destruction and osteophyte formation.
本研究旨在证明一种新开发的 c-Fos/激活蛋白 (AP)-1 选择性抑制剂 T-5224 可抑制人关节软骨细胞中基质金属蛋白酶 (MMPs) 的表达,并预防骨关节炎 (OA) 诱导的小鼠模型中的软骨破坏。首先,我们通过实时聚合酶链反应检测 T-5224 对人关节软骨细胞中 MMP 和炎性细胞因子表达的影响。我们通过内侧半月板 (DMM) 不稳定在小鼠中创建 OA 模型。T-5224 每天口服一次,并通过组织学、免疫组织化学和微计算机断层扫描 (CT) 分析评估 OA 病理。T-5224 抑制了 IL-1 刺激的人软骨细胞中 MMP-1、3 和 13 以及白细胞介素 (IL)-1β、肿瘤坏死因子 (TNF)-α 和 IL-6 的 mRNA 表达水平。OA 诱导的小鼠口服 T-5224 可预防软骨破坏。T-5224 治疗组的组织学评分明显优于载体治疗组。免疫组织化学染色显示 T-5224 治疗组的 X 型胶原和 MMP-13 没有增加。微 CT 分析显示载体治疗组股骨髁和胫骨前内侧有轻度但明显的骨赘形成,但 T-5224 治疗组没有。综上所述,c-Fos/AP-1 的特异性抑制以及由此导致的广谱下游 MMPs 和炎性细胞因子的转录激活抑制,可有效预防软骨破坏和骨赘形成。